The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis ; volume:8 ; number:1 ; day:6 ; month:9 ; year:2018 ; pages:1-10 ; date:12.2018
Scientific reports ; 8, Heft 1 (6.9.2018), 1-10, 12.2018
- Urheber
-
Passiglia, Francesco
- Beteiligte Personen und Organisationen
-
Rizzo, Sergio
Maio, Massimo Di
Galvano, Antonio
Badalamenti, Giuseppe
Listì, Angela
Gulotta, Leonardo
Castiglia, Marta
Bazan, Viviana
Russo, Antonio
Fulfaro, Fabio
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-30780-4
- URN
-
urn:nbn:de:101:1-2018102117413751727393
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Passiglia, Francesco
- Rizzo, Sergio
- Maio, Massimo Di
- Galvano, Antonio
- Badalamenti, Giuseppe
- Listì, Angela
- Gulotta, Leonardo
- Castiglia, Marta
- Bazan, Viviana
- Russo, Antonio
- Fulfaro, Fabio
- SpringerLink (Online service)
Ähnliche Objekte (12)
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen
Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen
Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
Therapie des fortgeschrittenen NSCLC – Erlotinib jetzt zur Erstlinientherapie bei Patienten mit EGFR-Mutation zugelassen
Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
EGFR exon 20 insertion mutations in NSCLC
Sulforaphane attenuates EGFR signaling in NSCLC cells